Anne Rigg

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Leticia Monin, Adam G. Laing, Miguel Muñoz‐Ruiz et al. · The Lancet Oncology · 2021 · 608 citations · Full text

COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?

Beth Russell, Charlotte Moss, Anne Rigg et al. · ecancermedicalscience · 2020 · 297 citations · Full text

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 277 citations · Full text

Genetic Prodrug Activation Therapy for Breast Cancer: A Phase I Clinical Trial of<i>erb</i>B-2–Directed Suicide Gene Expression

Hardev Pandha, Lesley‐Ann Martin, Anne Rigg et al. · Journal of Clinical Oncology · 1999 · 145 citations

Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients

Mary O’Brien, Alison Borthwick, Anne Rigg et al. · British Journal of Cancer · 2006 · 130 citations · Full text